Status:
NOT_YET_RECRUITING
Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management
Lead Sponsor:
Dr. Asma Abdus Salam
Conditions:
Cholecystectomy
Hernia, Abdominal
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
The goal of this study is to identify the genes as well as their association with Nalbuphine. This will help the investigator to identify opioid vulnerability in Pakistani population in the postoperat...
Detailed Description
The available data suggests that nalbuphine, tramadol, and morphine exhibit comparable efficacy in treating moderate to severe postoperative pain. However, significant individual variations exist in t...
Eligibility Criteria
Inclusion
- All adult men or women
- Age 18 to 70 years
- ASA criteria 1,2 and 3
- Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours
Exclusion
- Surgical procedure duration lasting more than 4 hours
- Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine,
- History of hypersensitivity or allergy to opioids,
- Pregnant or breastfeeding mothers,
- History of narcotic dependency, addiction, and withdrawal
- Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission
- Refusing to participate in the study
- Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT06996561
Start Date
September 1 2025
End Date
June 30 2027
Last Update
August 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ziauddin University
Karachi, Sindh, Pakistan, 755000